Group 1 - The core viewpoint of the article highlights that Zai Lab (ZLAB.US) saw a pre-market increase of 3.44%, reaching $35.49, following a report from CICC regarding the National Healthcare Security Administration's announcement on the preliminary review of drug directories [1] - A total of 534 drugs passed the preliminary review, indicating the expected launch of a dual-directory mechanism that will clarify the roles of basic medical insurance and commercial insurance for innovative drugs [1] - The report suggests that the combination of basic medical insurance support and the expansion of commercial insurance is likely to encourage commercial insurance companies to invest in innovative drug development through various means, providing stable long-term investment for R&D [1] Group 2 - The focus on high-value innovative drugs that are not covered by basic medical insurance but have significant clinical value is emphasized, which may lead to increased clinical penetration and enhanced market value for these drugs [1] - CICC recommends paying attention to stocks like Zai Lab, which may benefit from the new insurance policies and the potential for increased investment in innovative drug development [1]

Core Viewpoint - The National Healthcare Security Administration (NHSA) has announced the preliminary review results for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, with 534 drugs passing the initial review, indicating a significant step towards a dual catalog mechanism that promotes both basic insurance and innovative commercial insurance [1][2]. Group 1: Drug Catalog Overview - A total of 534 drugs were reviewed, with 310 drugs excluded from the catalog and 224 drugs included. The commercial insurance innovative drug catalog includes 121 drugs, with 12 drugs under non-exclusive agreements still in negotiation [2]. - The NHSA will continue to advance the basic catalog adjustments and the commercial insurance innovative drug catalog, including expert reviews in August-September, price negotiations in September-October, and results announcement in October-November [2]. Group 2: Dual Catalog Mechanism - The dual catalog mechanism establishes a clear division of responsibilities, where the basic medical insurance catalog covers essential clinical drugs, while the commercial insurance innovative catalog focuses on high-value drugs not covered by basic insurance but with significant clinical value [3]. - The framework encourages commercial insurance companies to invest in innovative drug development through various means, such as investment funds, to provide stable long-term funding for innovative drug research [3]. Group 3: Implications for Drug Development - The commercial insurance innovative drug catalog is a crucial step in developing a multi-tiered medication security system, addressing diverse medication needs of the population. It is believed that supplementing commercial insurance on top of basic insurance will facilitate the introduction of high-priced innovative drugs [4]. - Innovative drugs can accumulate real-world data and enhance clinical penetration through commercial insurance applications, thereby increasing their potential market value [4]. Group 4: Investment Recommendations - Companies to watch include BeiGene, Kelun-Biotech, CanSino Biologics, Innovent Biologics, and Zai Lab, along with other relevant companies such as CSPC Pharmaceutical Group, China National Pharmaceutical Group, and Hengrui Medicine [5].